<DOC>
	<DOCNO>NCT01709721</DOCNO>
	<brief_summary>The purpose study determine safety efficacy hydromorphone hydrochloride intrathecal administration use programmable implantable pump .</brief_summary>
	<brief_title>Safety Efficacy Study Hydromorphone Hydrochloride Intrathecal Administration Using Programmable Implantable Pump</brief_title>
	<detailed_description>A Controlled , Two-Arm , Parallel Group , Randomized Withdrawal Study Assess Safety Efficacy Hydromorphone Hydrochloride Delivered Intrathecal Administration Using Programmable Implantable Pump</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Subjects must meet follow criterion include : 1 . Subject must least 18 year age 75 year old . 2 . Clinically diagnosed chronic pain least 6month period . 3 . Subject presently intrathecal pain medication SynchroMed II Implantable pump meet clinical criterion implantation SynchroMed II Implantable pump . Subjects na√Øve intrathecal therapy , may enrol 2weeks pump implantation . 4 . Subject agree sign Pain Treatment Agreement ( Narcotic Contract ) limit narcotic prescription study physician . 5 . Subject must cognitively intact , opinion investigator , capable participation trial . 6 . Female subject childbearing potential must agree use medically acceptable effective doublebarrier method birth control . 7 . Subjects exist SynchroMed II Implantable pump reasonably expect benefit intrathecal opioid therapy . 8 . Subjects capable receive MRI without contrast CT myelogram , require study protocol . 9 . Provides write Ethics Committee approve informed consent . 10 . Willing comply study procedure requirements.. Subjects meet follow criterion exclude : 1 . Women pregnant breastfeed 2 . Subjects participate investigational drug device trial within 4 week prior enrollment . 3 . Subject know suspected allergy hydromorphone material infusion pump intrathecal catheter . 4 . Subject schedule pump catheter replacement within 6 month enrollment trial . 5 . Subject history dependence abuse opioids , stimulant , alcohol , benzodiazepine , define DSMIV criterion , within past year ( physical dependence prescribe opioid analgesic allow abuse opioids accord DSMIV permit , i.e . opioid addiction recreational use ) . 6 . Subjects show sign active systemic infection . 7 . Subjects metastatic cancer spinal canal know central nervous system contraindication intrathecal therapy . 8 . Subject condition require diathermy procedure . 9 . Subject life expectancy le 12 month . 10 . Subject independently comprehend participate require assessment , include respond VASPI , Shortform McGill Pain Questionnaire ( SFMPQ ) , Clinical Opiate Withdrawal Scale ( COWS ) , Subjective Opiate Withdrawal Scale ( SOWS ) , BPI patient global impression change ( PGIC ) measurement tool . 11 . Subject consider medically psychologically appropriate pump implantation . 12 . Subjects unable unwilling return require followup visit . 13 . Subjects active implanted device pacemaker , defibrillator , cochlear implant medical device use , opinion investigator device would interfere ability perform MRI CT myelogram . 14 . As result medical review physical examination , Investigator considers subject unfit study . 15 . Pain locate shoulder head neck region ( e.g . trigeminal neuralgia ) , central pain syndrome condition judge unlikely subject would benefit intrathecal administration drug product . 16 . Subjects previously unresponsive intrathecal hydromorphone therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hydromorphone</keyword>
	<keyword>Hydromorphone Hydrochloride</keyword>
	<keyword>Pain Management</keyword>
	<keyword>Non-narcotic analgesic</keyword>
</DOC>